Oxbryta / Voxelotor (Pfizer)

● CAMPAIGN OPEN PRE-LITIGATION / EMERGING 2 signals
Death / Stroke / Vaso-Occlusive Crisis (sickle cell)  ·  Voxelotor (Oxbryta)
DEFENDANT
Global Blood Therapeutics / Pfizer
MDL / DOCKET
Pre-MDL / Emerging
Emerging
JUDGE
TBD
PLAINTIFFS
Emerging
BELLWETHER / TRIAL
TBD
SETTLEMENT STATUS
None
📋 Case Overview

Oxbryta (voxelotor) was FDA-approved for sickle cell disease and then voluntarily withdrawn by Pfizer in September 2024 after a clinical trial showed patients taking the drug had higher rates of death, stroke, and vaso-occlusive crises compared to placebo. This is a very early-stage emerging tort with limited plaintiff filings.

⚗ CAUSATION SUMMARY

The HOPE trial extension data revealed statistically significant increased mortality and vaso-occlusive crisis events in the voxelotor arm. The mechanism is under investigation. Pfizer/GBT are alleged to have known about safety signals and delayed withdrawal.

⚖️ Litigation Status EMERGING
MDL / Court
No MDL yet — state court filing stage
Active Plaintiffs
Early — 500+ potential

Pfizer recalled Oxbryta (voxelotor) in November 2023 following post-market data showing increased mortality risk in sickle cell patients. Litigation is in early stages. No MDL formed. State court filings beginning. First-mover advantage for plaintiff firms.

Key Verdicts & Settlements
🔴
FDA recall — November 2023
Pfizer withdrew Oxbryta globally after interim data showed increased mortality. Strongest possible regulatory action.
⚖️
No verdicts yet — early litigation stage
First lawsuits filed 2024. MDL formation expected as cases accumulate.
📈
Filing trend: Emerging. First-mover advantage available. Pfizer recall is the strongest possible causation evidence. Sickle cell community is tight-knit — referral networks are the key campaign strategy.
📍 Geographic Exposure
●Nationwide — sickle cell patient population
●Highest concentration: Southeast (higher sickle cell prevalence), major medical centers
🏢 Key Defendants
DEFENDANT
ROLE
INTEL NOTE
Pfizer Inc.
Acquirer and marketer (acquired GBT 2022)
Withdrew drug Sept 2024 after clinical trial safety signals
Global Blood Therapeutics
Original developer
Merged into Pfizer; co-defendant
✅ Campaign Eligibility Criteria
✓Prescribed and took Oxbryta (voxelotor) for sickle cell disease
✓Experienced death, stroke, acute chest syndrome, or severe vaso-occlusive crisis
✓Treatment period: 2021–2024 (approval to withdrawal)
These criteria reflect general case strength indicators and are not legal advice. Contact CloudIntake to screen individual claimants.
📅 Litigation Timeline
2019
FDA approves voxelotor (Oxbryta) for sickle cell disease
2022
Pfizer acquires Global Blood Therapeutics for $5.4B
2024
HOPE trial extension data shows higher mortality in treatment arm
Sept 2024
Pfizer voluntarily withdraws Oxbryta from global market
2025
First lawsuits filed; MDL petition anticipated
Oxbryta / Voxelotor (Pfizer) — Intelligence Feed LIVE
📰 NEWS
Pfizer Reaches Settlement in Wrongful Death Lawsuit Linked to Withdrawn Sickle Cell Drug Oxbryta
Mar 13, 2026 Consumer Notice Read Source →
📰 NEWS
EU agency confirms continued suspension of SCD therapy Oxbryta
Mar 13, 2026 Sickle Cell Disease News Read Source →
Feed All Torts
MASS TORT AD AGENCY
First-mover advantage is real.
Oxbryta / Voxelotor (Pfizer) is early-stage — most firms haven't moved yet. MTAA launches education-first campaigns that build awareness and capture plaintiffs before the market wakes up.
Move First →
Plaintiff attorneys only · mtaa.ai
JACOB SCORE™
Oxbryta / Voxelotor (Pfizer)
44 / 100
ScienceModerate
MomentumDeveloping
CampaignDeveloping
TimelineDeveloping
VerdictsWeak
RARE DISEASE · PRE-TRIAL
Jacob Score™ — Methodology & Legal Disclaimers
The Jacob Score is a composite 1–100 litigation opportunity index for mass torts, produced by the TortIntel editorial team at Mass Tort Ad Agency. It is updated periodically as litigation conditions change.

Score Dimensions (each rated 1–5)

Science — Peer-reviewed study quality and quantity, relative risk magnitude, replication across independent research groups, FDA or regulatory action taken, and estimated Daubert survivability based on published expert testimony and prior rulings.

Momentum — MDL formation and phase, plaintiff count trajectory, case consolidation activity, and overall litigation velocity.

Campaign — Current filing window status, case saturation, defendant solvency, estimated qualifying population size, and co-defendant dynamics.

Timeline — Proximity to first expected resolution or bellwether trial, current discovery or Daubert phase, and estimated time-to-value for a signed plaintiff.

Verdicts — Confirmed plaintiff jury verdicts, bellwether trial win/loss record, and size or certainty of any established settlement fund. 1 = pre-trial · 2 = mixed early results · 3 = partial settlements or initial wins · 4 = confirmed large verdicts or funded settlement · 5 = landmark verdicts with formal settlement program.

LEGAL DISCLAIMERS

The Jacob Score and all associated content on TortIntel.ai is provided solely for mass tort business intelligence and law firm marketing decision-making purposes. It does not constitute legal advice, litigation strategy advice, or a recommendation to file or refrain from filing any lawsuit.

The Jacob Score is an editorial opinion based on publicly available data including court filings, published scientific literature, regulatory actions, and reported settlement information. It is not a guarantee of future litigation outcomes. Past verdicts and settlements are not predictive of future results in any specific case.

TortIntel.ai and Mass Tort Ad Agency make no representation that any score is complete, accurate, or current. Litigation conditions change rapidly. Attorneys must conduct independent due diligence and consult qualified co-counsel before making any case acquisition or litigation funding decisions based on this or any other intelligence tool.

This score must not be used to evaluate, accept, or reject any individual plaintiff’s case. Case-specific merit depends on individual facts, applicable state law, expert medical and scientific analysis, and jurisdiction-specific statutes of limitations — all of which are beyond the scope of this tool.

No attorney-client relationship is created by use of this platform. TortIntel.ai is not a law firm and does not provide legal services. © 2026 Mass Tort Ad Agency / TortIntel.ai. All rights reserved.
DATA ACCURACY
See something incorrect? Reach out and we'll fix it.
🔔 Alert Me
Get notified when Oxbryta / Voxelotor (Pfizer) updates.
✓ You're subscribed. We'll notify you of key developments.
TORTINTEL PRO
Abuse Discovery Tracker
Emerging institutional abuse cases — church, scouting, youth programs. Real-time defendant monitoring, filing window alerts, and filing cluster detection.
View Pro Features →